Company* (Symbol) |
Product | Description |
Indication |
Status (Date)** |
CANCER | ||||
Aastrom Biosciences Inc. (ASTM) |
Aastrom Replicell System | Automated clinical system designed to produce patient-specific cells for treatment of various diseases | Stem-cell therapy for patients with cancer |
Reported clincal trial results at the annual scientific meeting of the American Society of Hematology (11/30) |
Agouron Pharmaceuticals Inc.* | Prinomastat |
Matrix metalloprotease inhibitor | Patients with newly diagnosed glioblastoma multiforme following surgery and radiation therapy | Initiated Phase II trial (11/22) |
Allos Therapeutics Inc.* | RSR13 | Synthetic allosteric modifier of hemoglobin that noncovalently binds to hemoglobin, increasing oxygen delivery to hypoxic tissue | Patients with newly trial diagnosed glioblastoma multiforme receiving standard cranial radiation therapy |
Announced Phase II results (11/4) |
AnorMed Inc. (Canada; TSE:AOM) |
ZD 0473 |
Platinum-based chemotherapeutic agent designed to deliver an extended spectrum of activity and overcome classical platinum resistance | Various cancers | Initiated Phase I trial (11/18) |
Avax Technologies Inc. (AVXT) |
M-Vax | Individualized cell-based vaccine | Stage III melanoma | Announced nine-year, follow-up Phase II trial data (11/29) |
BioChem Pharma Inc. (Canada; TSE:BCH; BCHE) | Troxacitabine | Dioxolane nucleoside analogue |
Acute myelogenous leukemia | Announced results of Phase I trial (11/5) |
Biotherapies Inc.* | Mammastatin | Growth inhibitory protein isolated from normal breast tissue |
Advanced-stage breast cancer |
Initiated Phase I/II trials (11/10) |
Cell Pathways Inc. (CLPA) | Aptosyn (Exisulind) | A selective apoptotic, anti-neoplastic compound that inhibits a cyclic GMP phosphodiesterase and selectively induces apoptosis in pre-cancerous and cancerous cells, but not in normal cells |
Prostate cancer | Announced results of completed clinical trial (11/16) |
Cell Therapeutics Inc. (CTIC) |
Apra | Anticancer therapeutic that alters the phospholipid composition of tumor cells |
Chemotherapy-resistant sarcomas |
Announced Phase II results (11/23) |
Chiron Corp. (CHIR) and Ribozyme Pharmaceuticals Inc. (RZYM) |
Angiozyme | Ribozyme therapeutic that |
Various cancers cleaves target RNA in a highly specific manner by inhibiting the production of the vascular endothelial growth factor receptor | Initiated dosing of patients in Phase Ia and Phase Ib trials (11/16) |
Matrix Pharmaceutical Inc. (MATX) |
Intradose Injectable Gel | Collagen-containing gel that combines cisplatin and epinephrine, injected directly into tumor sites |
Primary liver cancer |
Announced Phase II results at the 17th Annual Chemotherapy Foundation Symposium in New York (11/3) |
Ontogen Corp.* | OC144-093 | P-glycoprotein inhibitor and multidrug resistance (MDR) modulator | MDR in cancer patients | Completed Phase I trial (11/16) |
OxiGene Inc. (Sweden; SSE: OXGN) |
Combretastatin A4 Prodrug |
Anti-tumor vascular targeting agent that attacks pre-existent tumor vasculature |
Patients with advanced malignancies | Announced interim Phase I results at the annual Mount Sinai Medical Center Chemotherapy Foundation Symposium XVII (11/5) |
Pharmacyclics Inc. (PCYC) | Xcytrin injection |
Motexafin gadolinium injection that augments the activity of radiation | Pediatric intrinsic pontine glioma | Initiated Phase I trial (11/19) |
Xcytrin injection | Motexafin gadolinium injection that augments the activity of radiation |
Cancer patients with brain metastases |
Announced Phase III results at the 41st Annual Meeting of the American Society for Therapeutic Radiology and Oncology (11/1) |
|
Protein Design Labs Inc. (PDLI) |
Smart M195 antibody | Humanized antibody that binds to the CD33 antigen on myeloid leukemia cells | Acute myelogenous leukemia |
Initiated Phase III trial (11/15) |
SuperGen Inc. (SUPG) | Nipent (FDA-approved) |
Pentostatin for injection; chemotherapeutic drug that inhibits adenosine deaminase (blocks DNA synthesis) |
Chronic lymphocytic leukemia |
Announced results of Phase I trial (11/7) |
Valentis Inc. (VLTS) |
Interferon-a | Recombinant cytokine protein that produces anti-tumor responses against cancer |
Malignant angio-endothelioma | Initiated Phase IIa trial (11/23) |
Vertex Pharmaceuticals Inc. (VRTX) |
Incel | Biricodar dicitrate; small-molecule drug that blocks two chemotherapy efflux pumps (MDR-1 and MRP) in chemotherapy-resistant cancer cells | Advanced hormone refractory prostate cancer |
Announced results of Phase II trial (11/18) |
Incel | Biricodar dicitrate; small-molecule drug that blocks two chemotherapy efflux pumps (MDR-1 and MRP) in chemotherapy-resistant cancer cells | Chemotherapy-resistant ovarian cancer |
Announced interim Phase II results (11/18) |
|
CARDIOVASCULAR | ||||
Centocor Inc. (a subsidiary of Johnson & Johnson; NYSE:JNJ) |
ReoPro (FDA-approved) | Abciximab; chimeric monoclonal antibody fragment to GPIIb/IIIa platelet receptor |
Stroke patients with increased risk of intracranial bleeding |
Announced Phase II results at the 72nd Scientific Sessions of the American Heart Association (11/7) |
Cor Therapeutics Inc. (CORR) |
Cromafiban |
Oral GP IIb/IIIa inhibitor | Patients with a history of acute coronary syndromes or cerebrovascular accidents |
Announced Phase II results at a symposium preceding the 72nd Annual Scientific Sessions of the American Heart Association (11/8) |
Discovery Therapeutics Inc.* and Medco Research Inc.* | MRE0470 |
Adenoscan; compound that causes coronary arterial dilation |
Diagnosis of coronary artery disease | Initiated Phase II trial (11/16) |
Icos Corp. (ICOS) |
LeukArrest | Humanized monoclonal antibody that that blocks CD11/CD18-mediated cell adhesion (inhibits movement of neutrophils from blood into tissue) |
Myocardial infarction | Announced Phase II results (11/3) |
Pharmacyclics Inc. (PCYC) | Antrin | Water-soluble photosensitizer that accumulates in atherosclerosis, is cleared rapidly from the blood and is activated by 732 nm of light; intravenously delivered |
Peripheral arterial disease | Announced Phase I results (11/10) |
United Therapeutics Corp. (UTHR) |
UT-15 |
Synthetically produced variation of the prostacyclin molecule |
Pulmonary hypertension | Completed patient enrollment in two Phase III trials (11/8) |
Valentis Inc. (VLTS) | | Plasmid-based, non-viral vascular endothelial growth factor gene medicine | Inhibition of restenosis following angioplasty |
Announced interim results of Phase II trial (11/10) |
DIABETES | ||||
Alteon Inc. (ALTNC) | Pimagedine |
Compound designed to block abnormal glucose/protein complexes (advanced glycosylation end products) | Preservation of renal function in patients with Type 1 diabetic neuropathy | Announced Phase III results |
Amylin Pharmaceuticals Inc. (AMLN) |
Symlin |
Pramlintide acetate; synthetic analogue of the hormone amylin |
Type I diabetes |
Announced Phase III results (11/8) |
INFECTION | ||||
Agouron Pharmaceuticals Inc. (a subsidiary of Warner-Lambert Co.; NYSE:WLA) | AG7088 | Synthetic compound designed to inhibit the rhinovirus 3C protease |
Rhinovirus infection |
Initiated clinical trial (11/4) |
Cel-Sci Corp. (AMEX:HIV) | HGP-30W |
Preventive vaccine for HIV-1 subtype C | HIV infection |
Announced Phase II results (11/22) |
Gilead Sciences Inc. (GILD) | | Tenofovir disoproxil fumarate; a nucleoside analogue for use in combination antiretroviral regimens |
HIV infection |
Commenced enrollment in Phase III multinational trial (11/30) |
Maxim Pharmaceuticals (AMEX:MMP) |
Maxamine |
H2 receptor agonist; combination therapy with interferon | Untreated hepatitis C infection | Announced preliminary Phase II results (11/8) |
Microcide Pharmaceuticals Inc. (MCDE) | RWJ-54428 |
Cephalosporin antibiotic infections |
Various bacterial | Commenced Phase I trials |
Trimeris Inc. (TRMS) and Hoffmann-La Roche Inc. | T-20 | Compound that inhibits fusion of HIV with host cells before the virus replicates and infects other cell |
Pediatric HIV infection | Initiated Phase I trial (11/30) |
Vertex Pharmaceuticals Inc. (VRTX) |
VX-497 | Inhibitor of inosine monophosphate dehydrongenase | Reduction of liver inflammation in hepatitis C infection |
Announced Phase II results (11/8) |
MISCELLANEOUS | ||||
Abgenix Inc. (ABGX) | ABX-IL8 |
Fully human monoclonal antibody that targets interleukin-8 | Psoriasis | Announced Phase I/II results (11/30) |
Adolor Corp.* | ADL 8-2698 |
Orally administered, gutselective narcotic antagonist | Narcotic-induced bowel dysfunction |
Announced Phase I/II results (11/10) |
Alexion Pharmaceuticals Inc. (ALXN) |
5G1.1 | Humanized anti-C5, anti-inflammatory complement inhibitor |
Rheumatoid arthritis | Announced clinical trial results (11/15) |
Angiotech Pharmaceuticals Inc. (Canada; TSE: ANP) | Micellar paclitaxel |
Yew tree-derived, semi-synthetic taxoid angiogenesis inhibitor | Secondary progressive multiple sclerosis |
Initiated Phase II trial (11/16) |
Axys Pharmaceuticals Inc. (AXPH) | APC-2059 |
Second-generation tryptase inhibitor |
Psoriasis |
Discontinued development based on interim Phase II evaluation (11/18) |
Biogen Inc. (BGEN) |
Antova |
Anti-CD40 ligand monoclonal antibody |
Renal transplantation and lupus nephritis |
Discontinued clinical trials due to adverse thrombo-embolic events (11/2) |
Biospecifics Technologies Corp. (BSTC) | Cordase |
Injectable collagenase | Dupuytren's disease |
Announced Phase II results (11/2) |
Cantab Pharmaceuticals plc (UK; LSE:CTB) |
Disc HSV vaccine |
Genetically disabled herpes simplex virus |
Genital herpes |
Commenced Phase II trial (11/4) |
Cellegy Pharmaceuticals Inc. (CLGY) | Anogesic |
Nitroglycerin ointment |
Chronic anal fissures |
Announced Phase III results (11/22) |
Centocor Inc. (a subsidiary of Johnson & Johnson (NYSE:JNJ) |
Remicade (FDA-approved) |
Infliximab; chimeric monoclonal antibody to tumor necrosis factor alpha |
Rheumatoid arthritis | Announced clinical trial results at the annual meeting of the American College of Rheumatology (11/15) |
Corixa Corp. (CRXA) |
AnergiX.RA | A complex of solubilized HLA with a specific peptide from the human cartilage glycoprotein HCgp39 | Rheumatoid arthritis | Presented interim Phase I data at the annual meeting of the American College of Rheumatology (11/17) |
Gilead Sciences Inc. (GILD) and Hoffmann-La Roche Inc. |
Tamiflu |
Oseltamivir phosphate; an oral neuraminidase inhibitor | Influenza |
Announced clinical trial results (11/8) |
The Immune Response Corp. (IMNR) |
IR501 and IR703 | Immune-based investigational vaccines |
Rheumatoid arthritis | Announced Phase IIb data at the annual meeting of the American College of Rheumatology (11/15) |
Immunex Corp. (IMNX) |
Enbrel (FDA-approved) |
Etanercept; recombinant, soluble T75 tumor necrosis factor (TNFr) linked to the Fc portion of human IgG1 | Rheumatoid arthritis |
Announced long-term clinical trial results at the annual meeting of the American College of Rheumatology (11/17) |
Incara Pharmaceuticals Corp. (INCR) | OP2000 | Oligosaccharide product derived from heparin with antithrombotic and anti-inflammatory |
Inflammatory bowel disease | Initiated Phase I trial (11/4) |
Isis Pharmaceuticals (ISIP) |
Isis 2302 |
Antisense oligonucleotide |
Rheumatoid arthritis |
Announced Phase II results at the annual meeting of the American College of Rheumatology (11/17) |
La Jolla Pharmaceutical Co. (LJPC) |
LJP 394 | Toleragen molecule that binds to surface of B cells and shuts off production of antibodies to double-stranded DNA | Lupus |
Announced Phase II/III results (11/30) |
MedImmune Inc. (MEDI) |
Synagis |
Palivizumab; humanized monoclonal antibody to respiratory syncytial virus; binds to fusion protein on viral surface (intramuscular injection) |
Pediatric respiratory syncytial virus disease | Announced clinical trial safety and efficacy data at the Second World Congress of Pediatric Infectious Disease (11/4) |
Miravant Medical Technologies Inc. (MRVT) |
PhotoPoint SnET2 | Photodynamic therapeutic |
Wet age-related macular degeneration |
Exceeded Phase III patient enrollment goal; closed patient enrolment (11/30) |
Neurocrine Biosciences Inc. (NBIX) |
NBI-34060 |
Sedative hypnotic | Transient insomnia |
Announced Phase II results (11/29) |
Protein Design Labs (PDLI) |
Zenapax (FDA-approved) |
Daclizumab; humanized monoclonal antibody (SMART, AntiTAC) |
Renal transplantation that binds to the interleukin-2 receptor on activated T cells | Announced new clinical results at the annual meeting of the American Society of Nephrology (11/4) |
Vertex Pharmaceuticals Inc. (VRTX) | VX-745 |
Orally administered, p38 mitogen-activated protein kinase inhibitor |
Rheumatoid arthritis | Commenced Phase II trial (11/2) |
Notes: | ||||
* Indicates a privately held company | ||||
** The dates listed indicate the issue dates of press releases, and are not necessarily the dates on which stated events took place. | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB: = Over the Counter Bulletin Board; SSE - Swedish Stock Exchange; TSE = Toronto Stock Exchange | ||||
ND = Not disclosed | ||||
